Literature DB >> 7283399

Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis.

P J Whitehouse, D L Price, A W Clark, J T Coyle, M R DeLong.   

Abstract

The nucleus basalis of Meynert provides diffuse cholinergic input to the neocortex. When compared with an age- and sex-matched control, the nucleus basalis from a patient with Alzheimer disease demonstrated substantial reduction of neurons. Loss of this neuronal population may represent an anatomical correlate of the well-documented cholinergic derangement in Alzheimer disease.

Entities:  

Mesh:

Year:  1981        PMID: 7283399     DOI: 10.1002/ana.410100203

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  270 in total

Review 1.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

Review 2.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

3.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

4.  Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments.

Authors:  Jean-Luc Picq; Fabienne Aujard; Andreas Volk; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2010-10-22       Impact factor: 4.673

5.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

7.  Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.

Authors:  L Preda; M Alberoni; S Bressi; C Cattaneo; J Parini; N Canal; M Franceschi
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Anti-amnesic effect of dimemorfan in mice.

Authors:  Hui-Hung Wang; Jyh-Wei Chien; Yueh-Ching Chou; Jyh-Fei Liao; Chieh-Fu Chen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

9.  Nucleus raphe dorsalis in parkinsonism-dementia complex of Guam.

Authors:  T Yamamoto; A Hirano
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

10.  Effect of cholinergic signaling on neuronal cell bioenergetics.

Authors:  Jianghua Lu; Lezi E; Nairita Roy; Lewis Hutfles; Eva Selfridge; Eric Funk; Jeffrey M Burns; Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.